These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19733029)

  • 1. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity.
    Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):431-4. PubMed ID: 19733029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
    Koomanachai P; Tiengrim S; Kiratisin P; Thamlikitkul V
    Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin and polymyxin B in critical care.
    Michalopoulos A; Falagas ME
    Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events.
    Petrosillo N; Chinello P; Proietti MF; Cecchini L; Masala M; Franchi C; Venditti M; Esposito S; Nicastri E
    Clin Microbiol Infect; 2005 Aug; 11(8):682-3. PubMed ID: 16008625
    [No Abstract]   [Full Text] [Related]  

  • 6. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
    Zavascki AP; Nation RL
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium.
    Fernandez-Viladrich P; Corbella X; Corral L; Tubau F; Mateu A
    Clin Infect Dis; 1999 Apr; 28(4):916-7. PubMed ID: 10825065
    [No Abstract]   [Full Text] [Related]  

  • 8. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Song JY; Lee J; Heo JY; Noh JY; Kim WJ; Cheong HJ; Hwang IS
    Int J Antimicrob Agents; 2008 Sep; 32(3):281-4. PubMed ID: 18650070
    [No Abstract]   [Full Text] [Related]  

  • 9. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.
    Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
    J Antimicrob Chemother; 2008 Jun; 61(6):1369-75. PubMed ID: 18367459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit.
    Holloway KP; Rouphael NG; Wells JB; King MD; Blumberg HM
    Ann Pharmacother; 2006 Nov; 40(11):1939-45. PubMed ID: 17018688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
    Levin AS; Barone AA; Penço J; Santos MV; Marinho IS; Arruda EA; Manrique EI; Costa SF
    Clin Infect Dis; 1999 May; 28(5):1008-11. PubMed ID: 10452626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.
    Sobieszczyk ME; Furuya EY; Hay CM; Pancholi P; Della-Latta P; Hammer SM; Kubin CJ
    J Antimicrob Chemother; 2004 Aug; 54(2):566-9. PubMed ID: 15269195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
    Kassamali Z; Jain R; Danziger LH
    Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymyxin B, colistin, and sodium colistimethate.
    Horton J; Pankey GA
    Med Clin North Am; 1982 Jan; 66(1):135-42. PubMed ID: 6278236
    [No Abstract]   [Full Text] [Related]  

  • 15. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
    Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
    Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
    Pintado V; San Miguel LG; Grill F; Mejía B; Cobo J; Fortún J; Martín-Dávila P; Moreno S
    J Infect; 2008 Mar; 56(3):185-90. PubMed ID: 18280570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?
    Tuon FF; Rymsza AM; Penteado-Filho SR; Pilonetto M; Arend LN; Levin AS
    J Infect; 2011 Mar; 62(3):246-9. PubMed ID: 21256151
    [No Abstract]   [Full Text] [Related]  

  • 18. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.
    Hartzell JD; Neff R; Ake J; Howard R; Olson S; Paolino K; Vishnepolsky M; Weintrob A; Wortmann G
    Clin Infect Dis; 2009 Jun; 48(12):1724-8. PubMed ID: 19438394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin.
    Katragkou A; Roilides E
    J Clin Microbiol; 2005 Sep; 43(9):4916-7. PubMed ID: 16145177
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical characteristics and risk factors of colistin-induced nephrotoxicity.
    Kim J; Lee KH; Yoo S; Pai H
    Int J Antimicrob Agents; 2009 Nov; 34(5):434-8. PubMed ID: 19726164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.